Quality-Technical Agreements - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality-Technical Agreements
Siegfried Schmitt, principal consultant at PAREXEL, discusses the importance of quality-technical agreements.


Pharmaceutical Technology
Volume 38, Issue 5, pp. 70

Q.We are part of a multinational company, and some regulated activities, such as supplier audits, are pooled at the corporate head office. In a recent internal audit, we received a finding that there were no quality agreements in place between the site and the head office covering these activities. Surely, as we are one company, no such agreements are needed?

A.‘If it is not documented, there is no proof of evidence.’ While the company may be following an old adage, internal auditors were correct in documenting this deviation from good practices. Close collaboration and a common understanding of work practices among staff does not absolve anyone from having documented processes, roles and responsibilities, and defined documentation requirements—all commonly referred to as a quality-technical agreement.

RELATED CONTENT

The Benefits of eClinical Systems in Supply-Chain Management

The Human Factor

The basis for this can be found in relevant regulations by the European Medicines Agency (EMA), FDA, the World Health Organization (WHO), Pharmaceutical Inspection Convention/Pharmaceutical Inspection Cooperation Scheme (PIC/S), and the International Conference on Harmonization (ICH) (1-5).

When looking for applicable regulations relating to quality-technical agreements, it is important to note that explicit references to such agreements do not always exist. It is, therefore, necessary to look for other terms, such as contract manufacture or outsourced activities.

Apart from being a regulatory requirement, these mandates make good business sense. Their aim is to reduce errors, timelines, and cost. They should clearly describe all elements of respective roles and responsibilities, inputs and outputs, and expectations from both sides.

Items to address in a quality-technical agreement include all aspects that affect the identity, quality, safety, potency, and purity of a product, and/or aspects that may affect compliance status of either the contract giver or contract acceptor (6). In a specific case in which suppliers are audited by a corporate function, the quality-technical agreement should clarify, as a minimum

  • Scope—all suppliers for equipment, raw materials, packaging materials, analyses, services, information technology
  • Roles and responsibilities—will there be a site review of the report required? What qualifications will be required of auditors?
  • Deliverables—audit plan, reports, timelines for issuing a report
  • Communication—regarding dispute resolution with the audited entity
  • Documentation—Is there a standard template for audits?

Finally, consider tracking agreement effectiveness through well-defined metrics. For every particular case, these metrics could include on-time delivery and in full (target 95%) and the number of audits overdue per quarter (target no more than 1; none for critical suppliers).

Just because activities are being outsourced, even if only to other entities within a company, this does not relieve a company of responsibility. On the contrary, a biopharmaceutical company must continue to assume responsibility, and quality-technical agreements are an important way to help ensure and retain this control.

References
1. EudraLex, Vol 4, Chapter 7 Outsourced Activities, accessed Apr. 11, 2014.
2. FDA, Guidance for Industry, Contract Manufacturing Arrangements for Drugs: Quality Agreements, Draft Guidance (May 2013).
3. WHO,Pharmaceutical Production and Related Technology Transfer, 2011, accessed Apr. 11, 2014.
4. PIC/S, GMP Guide PE 009-11 (Part I).
5. ICH,Q10 Pharmaceutical Quality System.
6. PDA, Technology and Knowledge Transfer, Keys to successful implementation and management (PDA, May 2014).

Siegfried Schmitt

About the Author
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses the importance of quality-technical agreements.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here